/

Empresas

Lu

No verificado

Lutris Pharma

Sobre qué escribimos

BiologíaEconomíaFarmacéuticaFinanzasSanidad

6 Comunicados de prensa

Ver todos los comunicados de prensa

Press Release cover image

07/07/2025

Salud

Fitness

Ferias y Congresos

Eventos

Medicina - Varios

Medio Ambiente/Ecología

Agricultura

Lutris Pharma Presents Additional Positive Data from Its Phase 2 Trial of LUT014 Gel Demonstrating Significant Efficacy in Treating Acneiform Rash Associated with Use of Anti-EGFR Cancer Therapies at the ESMO Gastrointestinal Cancers Congress 2025

Fuente

Editor

1.00

0

29/04/2025

Farmacéutica

Sanidad

Economía

Gestión empresarial

Administración de Empresas

Biología

Lutris Pharma Announces the Appointment of Seasoned Life Science Executive, Sumant Ramachandra, M.D., Ph.D., as Chief Executive Officer

Fuente

Editor

1.00

0

28/04/2025

Farmacéutica

Sanidad

Biología

Lutris Pharma Presents New Data from Its Completed Clinical Trial of LUT014 Gel Demonstrating Efficacy in Treating Acneiform Rash Associated with Use of Anti-EGFR Cancer Therapies at AACR Annual Meeting 2025

Fuente

Editor

1.00

0

26/03/2025

Farmacéutica

Sanidad

Finanzas

Biología

Lutris Pharma to Present at the American Association for Cancer Research Annual Meeting 2025

Fuente

Editor

1.00

0

Press Release cover image

28/01/2025

Farmacéutica

Sanidad

Finanzas

Banca

Préstamos

Ahorro/Finanzas personales

Leasing

Gestión de bonos y obligaciones

Fondos de inversión

Eurobonos

Biología

Lutris Pharma Secures $30 Million Financing to Advance the Development of Biopharmaceutical to Improve Anti-Cancer Drug Effectiveness

Fuente

Editor

1.00

0

Press Release cover image

15/10/2024

Farmacéutica

Sanidad

Biología

Lutris Pharma Completes Enrollment in Phase 2 Trial of LUT014 for the Treatment of EGFRI-Induced Acneiform Rash in Patients with Metastatic Colorectal Cancer

Fuente

Editor

1.00

0

Seguidores

0

Compatibilidad

0